March 23, 2022 Bio/Pharma/CRO Clinical Research/Diagn. Product Launch

GE Healthcare announces first patient dosed in phase III clinical trial for new dopamine transporter imaging radiopharmaceutical

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation of adult patients with suspected Parkinsonian syndromes, support research and improve patient care Builds on market leadership with SPECT agent DaTscan™ (Ioflupane I 123 Injection), to... Read more

March 10, 2022 Bio/Pharma/CRO Lab Top-10 Molecular Spectroscopy Product Launch

Announcing New Fourier 80 Benchtop FT-NMR Capabilities for Pharmaceutical and Food Analysis Markets

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announces new capabilities for its benchtop Fourier transform (FT) nuclear magnetic resonance (NMR) spectrometer, the Fourier 80, which does not require special lab infrastructure or cryogens, and offers excellent 1H sensitivity of 200:1 for gradient spectroscopy proton probes. A new adjustable temperature option increases experimental flexibility, while... Read more

February 16, 2022 Bio/Pharma/CRO Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 Product Launch

PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its SIRION Biotech business, a world leader in viral vector-based gene delivery technologies for gene and cell therapy and vaccine development, and the Centre for Genomic Regulation (CRG), an international... Read more

February 7, 2022 Bio/Pharma/CRO Lab Top-10 Mass Spectrometry Product Launch

Bruker Launches New timsTOF-based MALDI PharmaPulse® Solution for Label-free HTS in Drug Discovery

timsTOF MALDI PharmaPulse® (timsTOF MPP) for Unprecedented High-Throughput Screening (HTS) information content and throughput Innovative timsTOF platform combined with extreme MALDI PharmaPulse speed and robustness for unbiased, deep HTS and uHTS (ultra-high-throughput screening) Trapped Ion Mobility Spectrometry (TIMS): Exploiting ion mobility separation as a new dimension in HTS combined with high resolution QTOF-MS Enabling new... Read more

December 13, 2021 Bio/Pharma/CRO PAI Top-10

Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A

People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and a lack of treatment guidelines1,2 New data indicate that Hemlibra has a favourable safety profile in people with moderate or mild haemophilia A without factor... Read more

December 10, 2021 Bio/Pharma/CRO Product Launch

New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell... Read more

October 22, 2021 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1 The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study. This new test expands Roche’s... Read more